Atlas Trials

Phanes Therapeutics

3 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Phanes Therapeutics

RecordFirmDate
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (NCT05652686)Phanes Therapeutics2023-09-05
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) (NCT05482893)Phanes Therapeutics2023-03-15
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) (NCT05431270)Phanes Therapeutics2022-08-11

Track Phanes Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.